A federal judge in New York this week denied a motion from Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard to dismiss an antitrust lawsuit filed by AngioDynamics (NSDQ:ANGO) alleging unfair competition, according to an Albany Business Review report.
AngioDynamics filed the suit against Bard last May, claiming that the larger company illegally ties the sales of its peripherally inserted central catheters to its tip location devices.
In the suit, filed in the U.S. District Court for Northern New York, AngioDynamics accuses Bard of unfairly maintaining its dominant position in the tip location market by only selling its proprietary offering with its own catheters. The suit seeks to end the alleged anti-trust violations, triple damages and legal costs, the company said.
Bard’s legal counsel sought to dismiss the suit, claiming that AngioDynamics filed it because it is unable to compete in the marketplace, according to the Albany Business Review report.
Judge Brenda Sannes sided with AngioDynamics and denied the motion, according to the report.
“AngioDynamics has stated enough factual allegations rendering its claim of anticompetitive effects plausible at this early stage of the case. Therefore, Bard’s motion to dismiss must be denied,” Sannes wrote, according to the Albany Business Review.
In July, BD’s Bard won a third inferior vena cava filter bellwether case after the statute of limitations expired on the claims, according to court documents.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.